Skip Navigation



NDT Advance Access published online on March 1, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh658
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/4/743    most recent
gfh658v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Izzedine, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Izzedine, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Received June 23, 2004
Accepted October 13, 2004

Original Articles

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study

Hassane Izzedine 1*, Jean Sebastien Hulot 2, Daniel Vittecoq 3, Joel E. Gallant 4, Schlomo Staszewski 5, Vincent Launay-Vacher 1, Andrew Cheng 6, Gilbert Deray 1, and for the Study 903 Team

1 Department of Nephrology, Pitie-Salpêtrière Hospital, Paris, France
2 Department of Clinical Pharmacology, Pitie-Salpêtrière Hospital, Paris, France
3 Department of Infectious Diseases, Kremlin Bicêtre Hospital, Paris, France
4 Johns Hopkins University School of Medicine, Baltimore, MD
5 University Hospital, J. W. Goethe-Universität, Frankfurt, Germany
6 Gilead Sciences, Foster City, CA, USA

* To whom correspondence should be addressed.
Hassane Izzedine, E-mail: izzedine{at}psl.ap-hop-paris.fr



  Abstract

Background. Tenofovir disoproxil fumarate (TDF) was developed for the treatment of human immunodeficiency virus (HIV) infection. However, controlled data are sparse on the long-term renal tolerability of TDF at the currently approved daily dose of 300 mg in treatment-naive HIV-infected patients.

Methods. Over 144 weeks, this 600 patient, multicentre randomized, placebo-controlled, double-blind trial compared stavudine (301 patients) and TDF (299 patients), both administered in combination with lamivudine and efavirenz, in antiretroviral-naïve patients. TDF or placebo and stavudine or placebo were administered in an open-label fashion. All medications were taken orally. At screening, all patients had serum creatinines <1.5 mg/dl, calculated creatinine clearances ≥60 ml/min and a serum phosphorus ≥2.2 mg/dl.

Results. The incidences of grades 1 (≥0.5 mg/dl increase from baseline), 2 (2.1-3.0 mg/dl) and 3 (3.1-6.0 mg/dl) serum creatinine elevations at week 144 were 4, <1 and 0%, respectively, in the TDF group and 2, 0 and <1% in the stavudine control group (P = NS). There were no grade 4 (>6 mg/dl) serum creatinine elevations. At week 144, there was no change from baseline in the mean (0.83 mg/dl) serum creatinine in the TDF group compared with a 0.1 mg/dl decrease from baseline (0.83 mg/dl) in the stavudine control group. The incidences of grades 1 (2.0-2.2 mg/dl), 2 (1.5-1.9 mg/dl) and 3 (1.0-1.4 mg/dl) hypophosphataemia at week 144 were 4, 3 and <1%, respectively, in the TDF group and 4, 2 and <1% in the control group (P = NS). No patient experienced grade 4 (<1.0 mg/dl) hypophosphataemia. At week 144, the decrease ({Delta}) of mean serum phosphorus levels from baseline in both groups was similar ({Delta} 0.2 from 3.6 mg/dl for the TDF group, and 0.1 from 3.5 mg/dl for the stavudine control group). No patient developed Fanconi's syndrome or proximal renal tubular dysfunction during the study.

Conclusion. Through 144 weeks, TDF and stavudine, each administered in combination with efavirenz and lamivudine, had similar renal safety profiles in treatment-naive HIV-infected patients with normal renal function at baseline.

Keywords: long-term renal safety; tenofovir; tubulopathy.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
K. K. A. Van Rompay, L. Durand-Gasselin, L. L. Brignolo, A. S. Ray, K. Abel, T. Cihlar, A. Spinner, C. Jerome, J. Moore, B. P. Kearney, et al.
Chronic Administration of Tenofovir to Rhesus Macaques from Infancy through Adulthood and Pregnancy: Summary of Pharmacokinetics and Biological and Virological Effects
Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3144 - 3160.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. Grunfeld, D. P. Kotler, D. K. Arnett, J. M. Falutz, S. M. Haffner, P. Hruz, H. Masur, J. B. Meigs, K. Mulligan, P. Reiss, et al.
Contribution of Metabolic and Anthropometric Abnormalities to Cardiovascular Disease Risk Factors
Circulation, July 8, 2008; 118(2): e20 - e28.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
H. Izzedine, A. Baumelou, and G. Deray
Acute renal failure in HIV patients
Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2757 - 2762.
[Full Text] [PDF]

Home page
 J Int Assoc Physicians AIDS Care (Chic Ill)Home page
B. Young, K. Buchacz, R. K. Baker, A. C. Moorman, K. C. Wood, J. Chmiel, J. T. Brooks, and HIV Outpatient Study Investigators
Renal Function in Tenofovir-Exposed and Tenofovir-Unexposed Patients Receiving Highly Active Antiretroviral Therapy in the HIV Outpatient Study
J Int Assoc Physicians AIDS Care (Chic Ill), September 1, 2007; 6(3): 178 - 187.
[Abstract] [PDF]

Home page
 Mayo Clin Proc.Home page
T. I. de Silva, F. A. Post, M. D. Griffin, and D. H. Dockrell
HIV-1 Infection and the Kidney: An Evolving Challenge in HIV Medicine
Mayo Clin. Proc., September 1, 2007; 82(9): 1103 - 1116.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Gayet-Ageron, J. Ananworanich, T. Jupimai, P. Chetchotisakd, W. Prasithsirikul, S. Ubolyam, M. Le Braz, K. Ruxrungtham, J. F. Rooney, B. Hirschel, et al.
No change in calculated creatinine clearance after tenofovir initiation among Thai patients
J. Antimicrob. Chemother., May 1, 2007; 59(5): 1034 - 1037.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. Vidal, J. C. Domingo, J. Guallar, M. Saumoy, B. Cordobilla, R. Sanchez de la Rosa, M. Giralt, M. L. Alvarez, M. Lopez-Dupla, F. Torres, et al.
In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other Antiretrovirals in Human Renal Proximal Tubule Cells
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3824 - 3832.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
W. E. Delaney IV, A. S. Ray, H. Yang, X. Qi, S. Xiong, Y. Zhu, and M. D. Miller
Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus.
Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2471 - 2477.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.